Monday, August 9, 2021, Big Island, Hawaii, 1:00 PM – 2:30 PM HST (7:00 PM – 8:30 PM ET)
Expert Second Opinion — Investigators Discuss How They and Their Colleagues Navigate Emerging Clinical Research and Challenging Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Held in Conjunction with the 2021 Pan Pacific Lymphoma Conference
This event will be webcast live. Please see Registration tab for details.
There is no fee to participate in this satellite symposium program or live webcast of this event. However, in order to attend the in-person event you must be registered for the 2021 Pan Pacific Lymphoma Conference.
Faculty Krishna Gundabolu, MD
Associate Professor
Hematology-Oncology
University of Nebraska Medical Center
Omaha, Nebraska
Richard M Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Dana-Farber Cancer Institute
Boston, Massachusetts
Eunice S Wang, MD
Chief, Leukemia Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Consulting Faculty Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland
Wendy Stock, MD
Anjuli Seth Nayak Professor of Leukemia Research
University of Chicago Medicine and Comprehensive Cancer Center
Chicago, Illinois
Moderator Harry Paul Erba, MD, PhD
Director, Leukemia Program
Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina
This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company and Takeda Oncology.
MODULE 1: Management of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Ineligible for Intensive Induction Therapy — Dr Stone
Factors in the selection of initial therapy for patients with newly diagnosed AML; identification of individuals not eligible for intensive induction treatment
Key findings from the Phase III VIALE-A and VIALE-C trials evaluating venetoclax in combination with azacitidine and with low-dose cytarabine, respectively, as first-line treatment for patients with AML who are not eligible for intensive chemotherapy
Incidence of tumor lysis syndrome and other adverse events associated with venetoclax for AML; implications for the implementation of prophylactic measures in routine practice
Other available and investigational therapeutic approaches for older patients with newly diagnosed AML who are not eligible for intensive induction therapy
MODULE 2: Current and Emerging Strategies for Younger Patients with Previously Untreated AML — Dr Erba
Available data with venetoclax in younger, fit patients with newly diagnosed AML; current nonresearch role and ongoing investigations for previously untreated high- risk disease
Long-term efficacy and safety data from the pivotal Phase III trial comparing CPX-351
to standard 7 + 3 for newly diagnosed secondary AML; optimal integration of CPX-351 into practice and ongoing evaluation for primary AML
Pharmacologic differences between oral azacitidine (CC-486) and injectable azacitidine; effects on activity and tolerability
Efficacy and safety outcomes from the QUAZAR AML-001 study supporting the FDA approval of CC-486 as maintenance therapy; clinical implications for routine practice and future research
Ongoing Phase III studies assessing maintenance therapy for patients who receive intensive induction therapy with and without transplant (eg, AMADEUS, VIALE-T, VIALE-M)
MODULE 3: Clinical Decision-Making for Patients Diagnosed with AML and an Actionable Mutation — Dr Wang
Optimal approaches to the management of newly diagnosed or relapsed/refractory AML with a FLT3 mutation; appropriate integration of gilteritinib into routine practice
Available data with gilteritinib combined with standard induction or consolidation chemotherapy for newly diagnosed AML; ongoing investigations of gilteritinib and other novel FLT3 inhibitors
Research database supporting the FDA approvals of ivosidenib and enasidenib for patients with AML with IDH1 and IDH2 mutations, respectively; ongoing evaluation of these agents, including for newly diagnosed disease
Recognition and management of common and less frequent adverse events observed with FLT3 and IDH inhibitors
Efficacy of venetoclax-based therapy in patients with FLT3, IDH1 or IDH2 mutations; ongoing research assessing venetoclax in combination with targeted therapy
MODULE 4: Current and Future Treatment Considerations for Patients with Myelodysplastic Syndromes (MDS) — Dr Gundabolu
Key efficacy and safety findings from the Phase III MEDALIST trial evaluating luspatercept in patients with lower-risk MDS after failure of an erythropoiesis-stimulating agent who require red blood cell transfusions; FDA approval of luspatercept and optimal integration into practice
Response rates, duration of response and rates of transfusion independence achieved with oral decitabine/cedazuridine in the ASTX727-01-B and ASTX727-02 (ASCERTAIN) studies; FDA approval and current clinical role in comparison to standard IV decitabine
Available research findings with and ongoing evaluation of agents with established efficacy in AML (venetoclax, IDH inhibitors, et cetera) for patients with MDS
Early activity and safety data with and ongoing evaluation of promising novel agents (eg, pevonedistat, magrolimab) for MDS/AML; potential therapeutic roles
Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Learning Objectives
At the conclusion of this activity, participants should be able to
Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of AML.
Appreciate the FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML who are not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
Assess the FDA-approved indications for CPX-351 in patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
Review Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and consider how this novel strategy can be applied in clinical management.
Recall available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
Develop an understanding of the mechanisms of action of, available data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation.
Formulate a treatment algorithm for patients with lower- and higher-risk MDS, considering patient- and disease-related factors, including cytogenetic abnormalities.
Describe the biologic rationale for and mechanism of action of luspatercept in the treatment of anemia secondary to MDS, and appraise how this agent can be appropriately integrated into clinical practice.
Recall promising agents and combination strategies under investigation for AML and MDS, and counsel appropriately selected patients regarding clinical trial enrollment.
Accreditation Statement
In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS: The University of Nebraska Medical Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES: The University of Nebraska Medical Center designates this activity for 1.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Credit Form
A credit form will be given to each participant.
In order to receive credit, attendees must check in at registration and turn in a completed credit form at the conclusion of the activity. Credit certificates will be issued directly to attendees by UNMC CCE within 4 to 6 weeks after the symposium.
Disclosure Information
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.
All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
Disclosures
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:
FACULTY Krishna Gundabolu, MD – Advisory Committee: Blueprint Medicines, Bristol-Myers Squibb Company, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc; Contracted Research: Samus Therapeutics Inc; Ownership Interest (Stock Option): Geron. Mark Levis, MD, PhD – Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Menarini Group, Takeda Oncology; Contracted Research: Astellas, FUJIFILM Pharmaceuticals USA Inc. Wendy Stock, MD – Advisory Committee: Amgen Inc, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Pfizer Inc, Pluristem Therapeutics Inc, Servier, Syndax Pharmaceuticals Inc; Contracted Research: Pfizer Inc; Data and Safety Monitoring Board/Committee: Servier. Richard M Stone, MD – Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Aprea Therapeutics, Arog Pharmaceuticals Inc, BerGenBio ASA, Boston Pharmaceuticals, Bristol-Myers Squibb Company, ElevateBio, Foghorn Therapeutics, GEMoaB, GlaxoSmithKline, Innate Pharma, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Onconova Therapeutics Inc, Syros Pharmaceuticals Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Syntrix Pharmaceuticals, Takeda Oncology. Eunice S Wang, MD – Advisory Committee: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Kura Oncology, Novartis, PharmaEssentia, Stemline Therapeutics Inc; Consulting Agreements: Mana Therapeutics, Rafael Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Rafael Pharmaceuticals Inc; Speakers Bureau: Astellas, DAVA Oncology, Kura Oncology, Stemline Therapeutics Inc.
MODERATOR — Harry Paul Erba, MD – Advisory Committee and Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Syros Pharmaceuticals Inc, Takeda Oncology, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Daiichi Sankyo Inc, FORMA Therapeutics, Forty Seven Inc, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, PTC Therapeutics; Independent Review Committee: AbbVie Inc; Speakers Bureau: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.
THE UNIVERSITY OF NEBRASKA MEDICAL CENTER (UNMC) and RESEARCH TO PRACTICE (RTP) PLANNERS, STAFF AND REVIEWERS — The below planning committee members have nothing to disclose: Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC — RTP Reviewer, and Kathryn Ault Ziel, PhD — RTP Staff and Planner.
Supporters
This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company and Takeda Oncology.
Location
Fairmont Orchid
1 North Kaniku Drive
Kohala Coast, HI 96743
Hotel Phone: (808) 885 2000
Meeting Room
Grande Ballroom (Lobby Level)
Directions
The Fairmont Orchid is the host hotel for the 2021 Pan Pacific Lymphoma Conference.
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.
There is no fee to participate in this satellite symposium program or live webcast of this event.
Registration for in-person symposium
In order to attend the in-person symposia event you must be registered for the 2021 Pan Pacific Lymphoma Conference.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
